More

    Strong Technologies growth and improved margins By Investing.com



    GOTHENBURG, Sweden, July 17, 2024 /PRNewswire/ —

    Second quarter  

    • Sales of SEK 941 (905) million, an increase of 4% in local currencies and 4% in SEK.
    • Sales per region, in local currencies was -5% in APAC, +11% in EMEA and +5% in Americas.
    • Sales growth per business area, in local currencies, was +3% in Consumables, +40% in Technologies and -7% in Genetics.
    • Gross margin increased to 59.9% (55.8).
    • Operating income before depreciation and amortisation (EBITDA) increased to SEK 327 (293) million, giving an EBITDA margin of 34.7% (32.4).
    • Operating cash flow increased to SEK 236 million (211).
    • Net income increased to SEK 143 (106) million, giving earnings per share of SEK 1.06 (0.78).
    • Vitrolife Group acquired the distribution activities of medical devices from EMB, our Iberian distributor.
    • Vitrolife Group acquired eFertility (STB Zorg B.V.).

    First half year

    • Sales of SEK 1,782 (1,759) million, an increase of 2% in local currencies and 1% in SEK.
    • Sales per region, in local currencies was +6% in APAC, +4% in EMEA and -4% in Americas.
    • Sales per business area, in local currencies was +8% in Consumables, +23% in Technologies and -10% in Genetics.
    • Gross margin increased to 58.6% (56.3).
    • Operating income before depreciation and amortisation (EBITDA) increased to SEK 600 (554) million, giving an EBITDA margin of 33.6% (31.5).
    • Operating cash flow increased to SEK 434 million (372).
    • Net income increased to SEK 258 (205) million, giving earnings per share of SEK 1.91 (1.52).              

    Gothenburg, July 17, 2024
    VITROLIFE AB (publ)Bronwyn Brophy O ´Connor, CEO

    This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 17-07-2024 08:00 CET.

    Contact: Patrik Tolf, CFO, phone +46 (0) 31 766 90 21

    This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/vitrolife-ab–publ-/r/interim-report-q2–2024–strong-technologies-growth-and-improved-margins,c4015708

    The following files are available for download:

    https://mb.cision.com/Main/1031/4015708/2918602.pdf

    Interim report Q2, 2024

     


    https://i-invdn-com.investing.com/news/World_News_9_800x533_L_1420026261.jpg



    Source link
    Investing.com

    Latest articles

    spot_imgspot_img

    Related articles

    spot_imgspot_img